贫血产妇产后出血:评估临床试验结局指标
产后出血是全球孕产妇死亡的主要原因,贫血产妇无法耐受与健康产妇相同量的失血,但所有产妇使用相同的产后出血定义。该文利用WOMAN-2试验的盲态数据(4521例)分析贫血产妇产后出血的不同定义,评估其频率、对显著出血的特异性和与母亲功能的相关性,认为「临床诊断的产后出血」适合作为WOMAN-2试验的主要结局。
要点
- 贫血产妇产后出血定义不统一,临床试验最合适的结局指标尚待明确。
- 「临床诊断的产后出血」在WOMAN-2盲态数据中频率为7%,对休克指数≥1的特异性为95%。
- 「临床诊断的产后出血」与产后母亲功能恶化相关,作者认为适合作为WOMAN-2主要结局。
核心结论
- 产后出血预防干预临床试验的结局指标应能有效且精确地估计治疗效应,并对女性具有重要意义;「临床诊断的产后出血」似乎符合这些标准,是WOMAN-2试验的合适主要结局。
研究设计与样本
- 该文利用WOMAN-2试验(评估氨甲环酸预防基线中度或重度贫血产妇产后出血)的盲态数据,分析4521例参与者的产后出血结局指标。
- WOMAN-2试验注册于ClinicalTrials.gov NCT03475342(2018年3月23日)、ISRCTN62396133(2017年12月7日)和Pan African Clinical Trial Registry PACTR201909735842379(2019年9月18日)。
主要发现
- 对每个结局指标评估了频率、对显著出血(定义为休克指数≥1.0)的特异性以及与疲劳(改良疲劳症状量表MFSI)、体力耐力(六分钟步行试验)和呼吸困难的相关性。
- 「临床诊断的产后出血」频率足够(7%),对早期休克临床征象高度特异(对休克指数≥1的特异性为95%),并与产后母亲功能恶化相关。
关键数值与推荐
- WOMAN-2试验的主要结局「临床诊断的产后出血」定义为估计失血量>500 ml或24小时内任何足以损害血流动力学稳定性的失血量。
- 显著出血定义为休克指数≥1.0。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum haemorrhage (PPH) is a leading cause of maternal mortality worldwide. Maternal anaemia greatly increases the risk of PPH, and over a third of all pregnant women are anaemic. Because anaemia reduces the oxygen-carrying capacity of the blood, anaemic women cannot tolerate the same volume of blood loss as healthy women. Yet the same blood loss threshold is used to define PPH in all women. The lack of an established PPH definition in anaemic women means the most appropriate outcome measures for use in clinical trials are open to question. We used data from the WOMAN-2 trial to examine different definitions of PPH in anaemic women and consider their appropriateness as clinical trial outcome measures. MAIN BODY: The WOMAN-2 trial is assessing tranexamic acid (TXA) for PPH prevention in women with moderate or severe anaemia at baseline. To obtain an accurate, precise estimate of the treatment effect, outcome measures should be highly specific and reasonably sensitive. Some outcome misclassification is inevitable. Low sensitivity reduces precision, but low specificity biases the effect estimate towards the null. Outcomes should also be related to how patients feel, function, or survive. The primary outcome in the WOMAN-2 trial, a 'clinical diagnosis of PPH', is defined as estimated blood loss > 500 ml or any blood loss within 24 h sufficient to compromise haemodynamic stability. To explore the utility of several PPH outcome measures, we analysed blinded data from 4521 participants. For each outcome, we assessed its: (1) frequency, (2) specificity for significant bleeding defined as shock index ≥1.0 and (3) association with fatigue (modified fatigue symptom inventory [MFSI]), physical endurance (six-minute walk test) and breathlessness. A clinical diagnosis of PPH was sufficiently frequent (7%), highly specific for clinical signs of early shock (95% specificity for shock index ≥1) and associated with worse maternal functioning after childbirth. CONCLUSION: Outcome measures in clinical trials of interventions for PPH prevention should facilitate valid and precise estimation of the treatment effect and be important to women. A clinical diagnosis of PPH appears to meet these criteria, making it an appropriate primary outcome for the WOMAN-2 trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03475342, registered on 23 March 2018; ISRCTN62396133, registered on 7 December 2017; Pan African Clinical Trial Registry PACTR201909735842379, registered on 18 September 2019.
引用
- Brenner A, Roberts I, Balogun E, et al. Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials. Trials. 2022. PMID: 35303924. doi:10.1186/s13063-022-06140-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。